<?xml version="1.0" encoding="UTF-8"?>
<ref id="B8-biomedicines-08-00060">
 <label>8.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rossi</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Pagliara</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Orteschi</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Dosa</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Sammarco</surname>
    <given-names>M.G.</given-names>
   </name>
   <name>
    <surname>Caputo</surname>
    <given-names>C.G.</given-names>
   </name>
   <name>
    <surname>Petrone</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Rindi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Zollino</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Blasi</surname>
    <given-names>M.A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Pembrolizumab as first-line treatment for metastatic uveal melanoma</article-title>
  <source>Cancer Immunol. Immunother.</source>
  <year>2019</year>
  <volume>68</volume>
  <fpage>1179</fpage>
  <lpage>1185</lpage>
  <pub-id pub-id-type="doi">10.1007/s00262-019-02352-6</pub-id>
  <pub-id pub-id-type="pmid">31175402</pub-id>
 </element-citation>
</ref>
